Full-year guidance was raised in Q1 2026, with CFO Bueker stating revenue is "up 40 basis points from our previous guide," while Q4 2025 positioned 2026 around the initial guide and a framework that ...

Breakthrough research focus: Trials are exploring optimal dialysis dosing, fluid removal in AKI, and liberalized diets for dialysis patients while testing new therapies for glomerular conditions.

The Los Angeles Chargers have cemented their pass-catching corps, and Mike McDaniel delivered a resounding endorsement of their weaponry.

Novo Nordisk (NVO) stock is in focus as semaglutide sales in India jump 40% after steep Wegovy/Ozempic price cuts in response ...